J Clin Neurol.  2016 Oct;12(4):468-475. 10.3988/jcn.2016.12.4.468.

Clinical Response to Valproate in Patients with Migraine

Affiliations
  • 1Department of Pharmacology, Toxicology and Therapeutics, Division of Physiology and Pathology, Showa University School of Pharmacy, Tokyo, Japan. masakazu@pharm.showa-u.ac.jp
  • 2Department of Neurology, Showa University School of Medicine, Tokyo, Japan.

Abstract

BACKGROUND
AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring system for predicting the clinical response to prophylactic therapy.
METHODS
We investigated clinical factors from the medical records of 95 consistent responders (CRs) and 24 inconsistent responders (IRs) to valproate.
RESULTS
Multivariate stepwise logistic regression analysis revealed that a history of hyperlipidemia and hay fever and the complication of depression or other psychiatric disorder were significant factors that independently contributed to a negative response, with odds ratios of 6.024 [no vs. yes; 95% confidence interval (CI)=1.616-22.222], 2.825 (no vs. yes; 95% CI=1.046-7.634), and 2.825 (no vs. yes; 95% CI=1.052-7.576), respectively. A predictive index (PI) of the clinical response to valproate in patients with migraine was calculated using the regression coefficients of these three factors as an integer, and the index was significantly higher for IRs than for CRs (1.46±1.10 vs. 0.69±0.74, mean±SD, p<0.001).
CONCLUSIONS
The obtained PI may represent an appropriate scoring system for predicting the responses in these patients.

Keyword

migraine; valproate; prophylaxis; hyperlipidemia; hay fever; depression; clinical response; risk factor
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr